
09/10/2025
For millions living with paralysis, recovery has long felt impossible. Now, a biotech company has developed a cell therapy using induced pluripotent stem cells (iPSCs) to repair spinal cord damage. These donor-derived cells can transform into neural cells, replacing those lost to injury. Unlike personalized treatments, this off-the-shelf therapy could be faster, more accessible, and more affordable. After four years of promising lab results, the first human trial has been approved in China, with hopes for wider use by 2028. If successful, this therapy could transform life for the 15 million people worldwide with spinal injuries turning the dream of walking again into reality.